Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris

References

• Torres T, Raposo I, Selores M. IL-17 blockade in psoriasis: friend or foe in cardiovascular risk? Am J Clin Dermatol. 2016;17:107–112. doi:10.1007/s40257-015-0166-026596991
   PubMed Web of Science ®Google Scholar
• Vassantachart JM, Soleymani T, Wu JJ. Comparison of phototherapy guidelines for psoriasis: a critical appraisal and comprehensive review. J Drugs Dermatol. 2016;15:995–1000.27538001
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4–5):490–495. doi:10.1016/j.autrev.2014.01.00824434359
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis of T-cells in psoriasis. Clin Dermatol. 2007;25(6):574–580. doi:10.1016/j.clindermatol.2007.08.01218021895
   PubMed Web of Science ®Google Scholar
• Zouein FA, Duhé RJ, Booz GW. JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors. 2011;29:245–252. doi:10.3109/08977194.2011.61494921892841
   PubMed Web of Science ®Google Scholar
• Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227–264. doi:10.1146/annurev.biochem.67.1.2279759489
   PubMed Web of Science ®Google Scholar
• Tepass U. FERM proteins in animal morphogenesis. Curr Opin Genet Dev. 2009;19:357–367. doi:10.1016/j.gde.2009.05.00619596566
   PubMed Web of Science ®Google Scholar
• Darnell JE. STATs and gene regulation. Science. 1997;277:1630–1635.9287210
   PubMed Web of Science ®Google Scholar
• Andrés RM, Hald A, Johansen C, Kragballe K, Iversen L. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. Exp Dermatol. 2013;22:323–328. doi:10.1111/exd.1220423614738
   PubMed Web of Science ®Google Scholar
• de Medeiros AK, Speeckaert R, Desmet E, Gele MV, Schepper SD, Lambert J. JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS One. 2016;16:1–16.
   Google Scholar
• Van de Kerkhof PC, Schalkwijk J. Psoriasis. J Am Acad Dermatol. 2008;11(5):48–55.
   Google Scholar
• Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510–518. doi:10.1016/j.clindermatol.2007.08.00318021886
   PubMed Web of Science ®Google Scholar
• Bilalovic N, Sandstad B, Torlakovic E. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. Mod Pathol. 2004;17:1251–1258. doi:10.1038/modpathol.380017415205682
   PubMed Web of Science ®Google Scholar
• Nada HR, El Sharkawy DA, Elmasry MF, Rashed LA. Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study. Arch Dermatol Res. 2018;310:39–46. doi:10.1007/s00403-017-1792-629127481
   PubMed Web of Science ®Google Scholar
• Smyth JF, Gourley C, Walker G, et al. Antiestrogen therapy is active in selected ovarian cancer cases; the use of letrozolin estrogen receptor-posative patients. Clin Cancer Res. 2007;13(12):3617–3622.17575226
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Akimoto T, Muromoto R, et al. Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo. J Immunol. 2011;187:181–189. doi:10.4049/jimmunol.110096721606247
   PubMed Web of Science ®Google Scholar
• Sohn SJ, Barrett K, Van Abbema A, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013;191:2205–2216. doi:10.4049/jimmunol.120285923894201
   PubMed Web of Science ®Google Scholar
• Ueda T, Bruchovsky N, Sadar M. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem. 2002;277:7076–7085. doi:10.1074/jbc.M10825520011751884
   PubMed Web of Science ®Google Scholar
• Mignogna C, Rosa DG. The histopathology of psoriasis. Reumatismo. 2007;46:46–48.
   Google Scholar
• Saeki Y, Nagashima T, Kimura S, Okada-Hatakeyama M. An ErbB receptor-mediated AP-1 regulatory network is modulated by STAT3 and c-MYC during calcium-dependent keratinocyte differentiation. Exp Dermatol. 2012;21:293–298. doi:10.1111/j.1600-0625.2012.01453.x22417306
   PubMed Web of Science ®Google Scholar
• Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med. 2009;87:523–536. doi:10.1007/s00109-009-0457-019330474
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328. doi:10.1146/annurev-med-051113-02453725587654
   PubMed Web of Science ®Google Scholar
• A V V, Kanno Y, Ferdinand JR, O’Shea JJ. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015;194:21–27. doi:10.4049/jimmunol.140270525527793
   PubMed Web of Science ®Google Scholar
• Li SQ, Wang P, Wang DM, et al. Molecular mechanism for the influence of gender dimorphism on alcoholic liver injury in mice. Hum Exp Toxicol. 2018;10:1–2.
   Google Scholar
• Saggini A, Sergio C, Andrea C. IL-6 as a druggable target in psoriasis: focus on pustular variants. J Immunol Res. 2014;137:541–542.
   Google Scholar
• Danziger O, Pupko T, Bacharach E, Ehrlich M. Interleukin-6 and interferon-a signaling via JAK1-STAT differentially regulate oncolytic versus cytoprotective antiviral states. Front Immunol. 2018;9:94–95. doi:10.3389/fimmu.2018.0009429441069
   PubMed Web of Science ®Google Scholar
• Elloso MM, Gomez-Angelats M, Fourie AM. Targeting the Th17 pathway in psoriasis. J Leukoc Biol. 2012;92:1187–1197. doi:10.1189/jlb.021210122962689
   PubMed Web of Science ®Google Scholar